Cellvera is a biopharmaceutical company focused on developing and commercializing antiviral therapies to transform patients’ lives. Cellvera holds exclusive worldwide rights to Qifenda (Favipiravir) 400mg/800mg and the injectable formulation. This broad-spectrum therapeutic has shown antiviral effects against SARS-CoV-2 (the virus responsible for causing COVID-19) and more than 20 other RNA viruses. Favipiravir is a broad-spectrum antiviral in oral tablet form, initially developed by FujiFilm Toyama in Japan, as a potent and broad-spectrum antiviral. The drug was approved in Japan in 2014 to treat pandemic influenza. The antiviral medication is effective against 12 families of viruses, including Coronaviruses (COVID, MERS, SARS), Filoviruses (EBOLA, MARBURG), Flaviviruses (ZIKA, WEST NILE, DENGUE), RABIES, NOROVIRUS, and many others.
